WinstonWınston
Uxin Limited logo

Uxin Limited

UXIN
9
Auto - Dealerships · Consumer Cyclical
Price
$1.69
+0.07 (+4.66%)
Market Cap
$370.4M
Exchange
NASDAQ
Winston Score
9
Winston is worried
Weak fundamentals across most pillars.

Share count rising — dilution

+5270.7% over 3y

The company has issued more shares over this period, which dilutes each existing shareholder’s stake.

Diluted shares outstanding: 3.9M (2022) → 209.2M (2025)

Uxin is a used car retailer based in China. It runs physical dealership locations where regular consumers can browse, test drive, and buy pre-owned vehicles. The company has shifted from an online-only marketplace model to a hybrid approach centered on large, inventory-holding "super stores," with its main location in Xian.

Uxin makes money by buying used cars, reconditioned them, and selling them directly to individual buyers at a markup — that direct retail model explains the thin 6.7% gross margin typical of car dealerships. The company operates entirely within China, a massive but competitive used car market that is still developing compared to mature markets like the US. Uxin has struggled with profitability, reflected in its negative operating and return-on-capital figures, and the key risk is whether it can scale its store network fast enough to reach the sales volume needed to cover fixed costs and turn a sustainable profit.

Winston Score History

Growth Profile

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

+95.0% YoY

YoY Growth Rate

Revenue accelerating

EPS Growth

+96.9% YoY

YoY Growth Rate

EPS growth accelerating

R&D Spend

$12M/ year

Rising (+13% vs prior year)

0.4% of revenue

Below sector average (4%)

R&D investment increasing — building for the future

Insider Activity

0.1%ownership

Flat

Insiders holding steady — not selling despite ability to

Cash Position

Cash flow positive

$83M cash & investments

Company generates more cash than it spends — no dilution risk from fundraising

Revenue accelerating

Uxin Limited grew revenue 95% year-over-year and the growth rate is speeding up. That's the kind of momentum growth investors look for — the question is whether margins can follow.

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Gross Margin
6.8%
Thin — 6.8% gross margin
Operating Margin
-5.6%
Losing money on operations — -5.6%
ROCE
-15.8%
Weak — -15.8% return on capital

Negative ROIC means the business is losing money on every dollar invested in it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales YoY
+76.9%
Fast-growing sales (76.9% YoY)
EPS YoY
N/A
Data not available
EPS Consistency
0/8 quarters
Earnings rarely grow — volatile business

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Cash Conversion
N/A
Data not available
FCF Margin
0.0%
Thin free cash flow (0.0%)

FCF margin between 0% and 10%. Some cash from sales, but not a lot.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

Debt / Equity
N/A
Data not available
Interest Cover
N/A
Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

P/E Ratio (TTM)
N/M
Negative earnings — P/E not meaningful
P/E vs Forward
N/A
not available
Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.
🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.
Start free trial